CN1923227A - Traditional Chinese medicinal formulation for treating ischemic cardiovascular and cerebrovascular diseases and preparation method thereof - Google Patents
Traditional Chinese medicinal formulation for treating ischemic cardiovascular and cerebrovascular diseases and preparation method thereof Download PDFInfo
- Publication number
- CN1923227A CN1923227A CN 200510014970 CN200510014970A CN1923227A CN 1923227 A CN1923227 A CN 1923227A CN 200510014970 CN200510014970 CN 200510014970 CN 200510014970 A CN200510014970 A CN 200510014970A CN 1923227 A CN1923227 A CN 1923227A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine preparation
- extract
- polyethylene glycol
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 24
- 230000000302 ischemic effect Effects 0.000 title claims description 15
- 239000000203 mixture Substances 0.000 title claims description 14
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract description 10
- 230000002526 effect on cardiovascular system Effects 0.000 title abstract description 8
- 238000009472 formulation Methods 0.000 title description 2
- 239000007901 soft capsule Substances 0.000 claims abstract description 28
- 239000006187 pill Substances 0.000 claims abstract description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 64
- 239000000284 extract Substances 0.000 claims description 41
- 239000003814 drug Substances 0.000 claims description 36
- 239000007788 liquid Substances 0.000 claims description 18
- 238000005406 washing Methods 0.000 claims description 17
- 239000011347 resin Substances 0.000 claims description 16
- 229920005989 resin Polymers 0.000 claims description 16
- 238000007598 dipping method Methods 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 238000005470 impregnation Methods 0.000 claims description 12
- 239000003921 oil Substances 0.000 claims description 12
- 235000019198 oils Nutrition 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 229920002545 silicone oil Polymers 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 6
- 239000003480 eluent Substances 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 229940057995 liquid paraffin Drugs 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- 238000005498 polishing Methods 0.000 claims description 6
- 238000005096 rolling process Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 238000001291 vacuum drying Methods 0.000 claims description 6
- 239000007766 cera flava Substances 0.000 claims description 5
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 5
- 235000012424 soybean oil Nutrition 0.000 claims description 5
- 239000003549 soybean oil Substances 0.000 claims description 5
- 230000000274 adsorptive effect Effects 0.000 claims description 4
- 239000012567 medical material Substances 0.000 claims description 3
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims description 2
- 230000003068 static effect Effects 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 3
- 244000046146 Pueraria lobata Species 0.000 abstract description 2
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 238000007670 refining Methods 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 13
- 239000012141 concentrate Substances 0.000 description 12
- 230000006837 decompression Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 238000004064 recycling Methods 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 206010008118 cerebral infarction Diseases 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 208000029078 coronary artery disease Diseases 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 5
- -1 and filters Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 3
- 229940114124 ferulic acid Drugs 0.000 description 3
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 3
- 235000001785 ferulic acid Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 208000026758 coronary atherosclerosis Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 description 2
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 description 1
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000007213 cerebrovascular event Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011162 core material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229930183842 salvianolic acid Natural products 0.000 description 1
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Abstract
The invention relates to a Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process, wherein the preparation is prepared from red sage root, kudzu vine root and Chuanxiong rhizome through extracting and refining, charging medicinal auxiliary materials and mixing homogenously, finally making soft capsules and dripping pills.
Description
Technical field
The invention belongs to the Chinese medicine preparation technical field, relate to a kind of Chinese medicine preparation that is used for the treatment of ischemic cardio cerebrovascular diseases, in particular, is a kind of soft capsule and drop pill and their preparation method that contains Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong extract.
Background technology
Cardiovascular and cerebrovascular disease is the No.1 killer who threatens global human health and life.In China, annual nearly 2,600,000 people die from cardiovascular and cerebrovascular disease, and every day, nearly 7,000 people died from cardiovascular and cerebrovascular disease, just had a people to die from cardiovascular and cerebrovascular disease in per 12 seconds.Ischemic cardio cerebrovascular diseases mainly comprises in coronary atherosclerotic heart disease (coronary heart disease), the ischemic cerebral apoplexy and transient ischemic attack.Wherein coronary heart disease is divided into acute coronary syndrome and stable angina pectoris again.The reason of cerebral infarction mainly comprises cerebral thrombosis and cerebral embolism, consequently cerebral infarction.
Ischemic cardio cerebrovascular diseases has common pathogenesis basis, i.e. coronary atherosclerosis pathological changes (atheromatous plaque).If the unstability plaque rupture in the coronary atherosclerosis pathological changes, thrombosis on this basis, lumen of vessels obvious stenosis or obturation, will cause heart or cerebrovascular events, these incidents comprise unstable angina pectoris above-mentioned, myocardial infarction, cerebral infarction and transient ischemic attack.
Cardiovascular and cerebrovascular disease causes limbs and intelligence disability, disablement, influences quality of life, long-term needs treatment and nursing, and is in hospital repeatedly.Life, health and material damage that cardiovascular and cerebrovascular disease brings for individual, family and society are inestimable.The annual expenses for medicine expenditure of cerebrovascular is more than 11,800,000,000 RMB.
Yet along with economic development, growth in the living standard, the life style of Chinese population takes place and great variety has all taken place dietary structure, from five sixties serve as main three high dietetics that are transformed into higher fatty acid, high protein, high heat with grain and vegetable, adding gets on the car enters popularizing of family, TV and computer, hypokinesia, and national overweight crowd has reached 200,000,000, obese people reaches 60,000,000, and middle age and old people's prevalence are approaching, and differentials between town and country are little.These life style and risk factor will cause the cardiovascular disease incidence rate to increase rapidly, estimate that the probability that China's middle age in 2010 suffers from a heart complaint will maintain an equal level with the U.S., it is high to welcome apoplexy simultaneously, the tide of the myocardial infarction zooming second time of cardiovascular disease.This will cause white elephant, and the economic growth of influence.Therefore the exploitation of this project has bigger social benefit and economic benefit.
At present, the prescription of promoting blood circulation has electuary and two kinds of dosage forms of oral liquid, all records in ministry standard.It mainly is made up of Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong and Radix Puerariae three flavor Chinese crude drugs, has the effect of blood circulation and channel invigorating.Be used for ischemic cardio cerebrovascular diseases, arteriosclerosis, cerebral thrombosis, cerebral ischemia, coronary heart disease, treatment of diseases such as angina pectoris.
Radix Salviae Miltiorrhizae is the conventional Chinese medicine of blood circulation promoting and blood stasis dispelling in the prescription, and salvianolic acid constituents wherein has antiplatelet aggregative activity, anti-thrombosis function, microcirculation improvement effect, anti-oxidative damage effect and multipath performance myocardium protecting action.
Rhizoma Chuanxiong in the prescription contains multiple compositions such as alkaloid, phenolic compound, lactone and neutral oils.Alkaloid main active ligustrazine very easily distils (22 ℃), and not soluble in water, is soluble in hot water, is dissolved in ethanol.The phenolic constituent master contains ferulic acid, and the ferulic acid water solublity is relatively poor, is dissolved in hot water, ethanol, and chemical stability is not high, and poor stability in aqueous solution sees that the light time decomposition is faster, and particularly high temperature sterilize is bigger to the destruction of ferulic acid.
But existing two kinds of dosage forms all exist in various degree shortcoming and deficiency, and for example, the electuary taking dose is big, takes inconvenience; Oral liquid is a liquid dosage form, and main effective ingredient salvianolic acid B is unstable in solution in the Radix Salviae Miltiorrhizae, and long-term storage can affect the treatment.What is more important, above-mentioned two kinds of dosage forms all can not keep the oiliness composition in the Rhizoma Chuanxiong, and the effective ingredient in the Rhizoma Chuanxiong oil has heart tonifying, increases the effect of coronary flow.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine preparation that is used for the treatment of ischemic cardio cerebrovascular diseases and preparation method thereof.It is to change traditional TONGMAI CHONGJI, oral liquid into soft capsule preparation and drop pill, applicating modern times technology enrichment effective site, improved bioavailability, reduced taking dose, reduced toxic and side effects, increased the types of drugs of treatment ischemic cardio cerebrovascular diseases,, satisfied the demand in market for doctor and patient provides different dosage forms.
The objective of the invention is to realize by following technical proposals:
Chinese medicine preparation of the present invention is a qi-circulation promoting soft capsule, and wherein, the ratio of extract and pharmaceutic adjuvant is 1: 1～5.
Described each components contents is preferably: the ratio of extract and pharmaceutic adjuvant is 1: 1～4.
Described each components contents is preferably: the ratio of extract and pharmaceutic adjuvant is 1: 3
Described pharmaceutic adjuvant is Petiolus Trachycarpi oil, Cera Flava, soybean oil or the like.
Chinese medicine preparation of the present invention is a pulse invigorating pill, and wherein the weight ratio of extract and Polyethylene Glycol is 1: 1～8.
Described each components contents is preferably: the weight ratio of extract and Polyethylene Glycol is 1: 1～6.
Described each components contents is preferably: the weight ratio of extract and Polyethylene Glycol is 1: 4.
Described Polyethylene Glycol is Polyethylene Glycol 100,1000,4000 or 6000 and their mixture.
The mixture of preferred especially Macrogol 4000 and polyethylene glycol 6000, its weight ratio is 1: 1～4.
The soft preparation technology of Chinese medicine preparation who is used for the treatment of ischemic cardio cerebrovascular diseases of the present invention comprises:
(1) Radix Salviae Miltiorrhizae 1250g, Radix Puerariae 1250g are ground into coarse powder, add 2～10 times of 40～80% ethanol of medical material weight, and room temperature dipping 2～5 times each 12～48 hours, merges impregnation liquid;
(2) concentrating under reduced pressure filters, and filtrate is crossed macroporous adsorptive resins, for example macroporous adsorptive resins AB-8 or D101.With the aqueous hydrochloric acid solution washing resin bed of pH2～7 of 3～10 times of amounts of column volume, wash post after, with 30～90% ethanol elutions of 2～5 times of amounts of column volume, collect eluent, concentrating under reduced pressure, vacuum drying, dry extract 50～200g, pulverize standby;
(3) Rhizoma Chuanxiong power is broken into coarse powder, adds 2～10 times of amount 60～90% ethanol, room temperature dipping 2～5 times, each 12～48 hours, merge impregnation liquid, concentrating under reduced pressure, static layering, Rhizoma Chuanxiong extract 50～150g, standby;
(4) preparation of soft capsule: according to the above ratio extract and pharmaceutic adjuvant are mixed and made into suspension.Be pressed into soft capsule rolling automatically on the mould machine.Through washing ball, drying, polishing, 1000 soft capsules, packing is promptly;
(5) preparation of drop pill: according to the above ratio extract is mixed with the adjuvant Polyethylene Glycol, stirring makes whole dissolvings and mix homogeneously, keep under 60～90 ℃ of constant temperatures, splash in liquid paraffin or the methyl-silicone oil in 5～10 ℃, be condensed into drop pill, exhaust liquid paraffin or methyl-silicone oil, the choosing grain, 10000 drop pill, promptly.
The present invention has adopted the method for macroporous resin eluting in conjunction with the technological means of modern industry, has improved the purity of Radix Salviae Miltiorrhizae, Radix Puerariae effective site, for Radix Salviae Miltiorrhizae, the more effective treatment ischemic cardio cerebrovascular diseases of Radix Puerariae extract provide necessary assurance.Test simultaneously by the different process method is compared, draw and adopt the room temperature dipping, and macroporous resin eluting process combined can improve the conclusion that Radix Salviae Miltiorrhizae, kudzu vine root make full use of.This technology can either adapt to suitability for industrialized production, has to have played the effect of giving full play to curative effect of medication.
Qi-circulation promoting soft capsule of the present invention has at utmost kept the active ingredient of three flavor medical materials, and taking convenience.Wherein, the adjuvant of soft capsule is an oil, adds gelatin-sealed, can be suspended in Rhizoma Chuanxiong oil, Radix Salviae Miltiorrhizae and the Radix Puerariae extract processing technique by the capsule core material of soft capsule in the oil, can fully keep the medicine active ingredient like this.Because all medicines have increased the stability of sour B of red acid and Rhizoma Chuanxiong volatile ingredient by the sealing of gelatin flexible glue skin, and do not have drug flavor when taking, the patient is acceptant.
Pulse invigorating pill is a kind of herbal mixture dropping pill formulation that modern high technology is produced of using, and, is splashed in the condensed fluid that mixes and formation through the suitable drip of bore with after the substrate heating and melting becomes solution by medicine.It has the title of solid solution, and dissolution rate is fast, bioavailability is high, and consumption is little, and the effect of having immediate effect.The medicine stability height that adopts drops to make, not facile hydrolysis, be difficult for oxidation, owing under liquid state, operate, no dust pollution, not influenced by crystal formation, be easy to guarantee the quality of medicine, it is quality controllable, dosage form is advanced, quick-acting, efficient, no gastric irritation, dissolving is fast, taking dose is little, stability is high.It is a kind of advanced person's form of Chinese drug.
Qi-circulation promoting soft capsule of the present invention, drop pill have improved bioavailability of medicament, simultaneously simple, the convenient needs that can satisfy the production of industrialization preferably of economic operation of the preparation technology of extract.
Qi-circulation promoting soft capsule of the present invention and pulse invigorating pill prove that in pharmacodynamic study this medical instrument has the drug action of obvious treatment coronary heart disease, and this medicine is expected to become the new good medicine of treatment ischemic cardio cerebrovascular diseases.
Below by effect experiment beneficial effect of the present invention is described.
Pharmacological action:
Pharmacological action shows that qi-circulation promoting soft capsule and pulse invigorating pill can the obvious experimental artery thrombosis times of prolong rats.Orally give qi-circulation promoting soft capsule and pulse invigorating pill have tangible curative effect to Acute Myocardial Ischemia in Rats.
The effectiveness of multiple model evaluation qi-circulation promoting soft capsule treatment cardiac-cerebral ischemia is adopted in this research, and compares with the TONGMAI KOUFUYE of having gone on the market.Experimental result shows:
Rats gavaged promotes blood circulation 5,10,20g crude drug/kg, and every day 1 time, continuous 5 days, can suppress in various degree because of the anterior descending coronary ligation causes raising of II lead electrocardiogram ST section, high dose 5min begins onset, keeps more than the 180min; Can dwindle myocardial infarct size, 5.7% (P＞0.05) that descended respectively, infarcted region/hazardous area, 18.2% (P＞0.05), 23.8% (P＜0.05), 12.5% (P＞0.05) that descended respectively, infarcted region/left chamber, 28.1% (P＜0.05), 31.3% (P＜0.05); Suppressing serum myocardium enzyme level raises, AST raises and has suppressed 14.3% (P＞0.05) respectively, 17.9% (P＜0.05), 20.5% (P＜0.05), LDH raises and has suppressed 9.4% (P＞0.05), 14.0% (P＞0.05) respectively, 16.1% (P＜0.05), CK-MB raises and has suppressed-0.5% (P＞0.05) respectively, 8.6% (P＞0.05), 24.6% (P＜0.05).Its function of resisting myocardial ischemia is suitable with isodose TONGMAI KOUFUYE.
Cause on the dog acute myocardial ischemia model in the ligation anterior descending coronary, duodenum promotes blood circulation 2,4,8g crude drug/kg, the degree of ischemia of epicardial electrogram mapping is obviously improved, with matched group relatively, 3 dosage groups, 36.8 ± 17.8% (P＜0.01) that descended respectively, 43.9 ± 20.3% (P＜0.01), 60.9 ± 14.3% (P＜0.001); The ischemia scope also has in various degree dwindles.Myocardial infarct size obviously dwindles, and has dwindled 5.9% (P＞0.05) respectively, 24.8% (P＜0.05), 29.7% (P＜0.05); High dose can obviously suppress the rising of Serum LDH cardiac muscle isozyme level, and middle and high dosage reduces myocardial oxygen consumption; To coronary flow, vascular resistance, system's blood pressure and heart rate do not make significant difference.Its intensity is suitable with TONGMAI KOUFUYE such as dosage such as grade.
Rats gavaged promotes blood circulation 5,10, behind 20g (crude drug)/kg/d, every day 1 time, continuous 5 days, can progressively improve its delayed ischemic neurological deficits degree, reduced by 14.9% (P＜0.05), 17.9% (P＜0.05), 22.4% (P＜0.01) than model control group to the 5th day its score value of administration.The cerebral infarction scope be can dwindle, 16.0% (P＞0.05), 29.0% (P＜0.05), 34.6% (P＜0.05) dwindled respectively; Can alleviate cerebral edema in various degree.Its intensity is suitable with TONGMAI KOUFUYE such as dosage such as grade.
Rat every day 1 time, gavaged in continuous 5 days and promote blood circulation 5,10,20g crude drug/kg can suppress the platelet aggregation that multiple derivant causes, inductive gathering has suppressed 23.6% (P＜0.05) respectively to adenosine diphosphate (ADP), 30.7% (P＜0.05), 49.2% (P＜0.001), gathering to arachidonic acid-induction has suppressed 4.4% (P＞0.05) respectively, 17.9% (P＜0.05), 26.9% (P＜0.01), inductive gathering has suppressed 23.5% (P＜0.05) respectively to CG, 42.8% (P＜0.001), 45.2% (P＜0.001); Can prolong the experimental artery thrombosis time that the damage of electricity irritation carotid artery intima is caused, prolong 14.7% (P＞0.05) respectively, 25.2% (P＜0.01), 45.6% (P＜0.001); Whole blood and the plasma viscosity of the hemorheology rat that the reduction macromolecule right rotary glycoside causes.Its function of promoting blood circulation to disperse blood clots is suitable with the liquid oral dosage such as grade.
Hemodynamics Study shows that duodenum promotes blood circulation 2, and 4g crude drug/kg does not have obvious influence to the every index of anesthetized open-chest dog hemodynamics, and the trend of reduction system blood pressure is arranged after 8g crude drug/kg administration, and significantly reduces total peripheral resistance.
Conclusion: the qi-circulation promoting soft capsule that is tried has obvious anti-cardiac-cerebral ischemia effect and function of promoting blood circulation to disperse blood clots, and its action intensity and oral liquid are suitable.
The Chinese medicine preparation that is used for the treatment of ischemic cardio cerebrovascular diseases of the present invention is qi-circulation promoting soft capsule and pulse invigorating pill, stipulate down to carry out test disintegration by an appendix capsule of version Chinese Pharmacopoeia in 2005 item: be disintegrate in 10～40 minutes the disintegration of this soft capsule, meets the pharmacopeia regulation; Be disintegrate in 5～30 minutes the disintegration of this drop pill, meets the pharmacopeia regulation.
The specific embodiment:
The following examples can help those skilled in the art more fully to understand the present invention, but do not limit the present invention in any way.
Embodiment 1
Preparation technology
Radix Salviae Miltiorrhizae 1250g, Radix Puerariae 1250g are ground into coarse powder, add 10 times of amount 80% ethanol room temperatures dippings 5 times, each 48 hours, merge impregnation liquid.Decompression recycling ethanol also concentrates, and filters, and filtrate is crossed macroporous adsorbent resin AB-8 post, aqueous hydrochloric acid solution washing resin bed with the pH7 of 10 times of amounts of column volume, after washing post,, collect eluent with 90% ethanol elution of 5 times of amounts of column volume, decompression recycling ethanol, concentrate, vacuum drying gets dry extract, pulverize, standby.
Rhizoma Chuanxiong power 1250g is broken into coarse powder, adds 10 times of amount 90% ethanol room temperatures dippings 5 times, each 48 hours, merges impregnation liquid.Decompression recycling ethanol concentrates, and layering gets Rhizoma Chuanxiong extract, and is standby.
(1). qi-circulation promoting soft capsule
Above-mentioned dry extract and Rhizoma Chuanxiong extract are merged, add adjuvant Petiolus Trachycarpi oil 10%, Cera Flava 5%, supply final quantity, make suspension with soybean oil.Be pressed into 1000 of soft capsules on the mould machine rolling automatically.Through washing ball, drying, polishing, packing are promptly.
(2). pulse invigorating pill
Dry extract and Rhizoma Chuanxiong extract are merged, add Polyethylene Glycol-4000, stir and make whole dissolvings and mix homogeneously, keep splashing in the liquid paraffin (5～10 ℃) under 60～90 ℃ of constant temperatures, be condensed into drop pill, exhaust liquid paraffin, the choosing grain, promptly.
Embodiment 2
Preparation technology
Radix Salviae Miltiorrhizae 1250g, Radix Puerariae 1250g are ground into coarse powder, add 2 times of amount 40% ethanol room temperatures dippings 2 times, each 12 hours, merge impregnation liquid.Decompression recycling ethanol also concentrates, and filters, and filtrate is crossed macroporous adsorbent resin D101 post, aqueous hydrochloric acid solution washing resin bed with the pH2 of 3 times of amounts of column volume, after washing post,, collect eluent with 30% ethanol elution of 2 times of amounts of column volume, decompression recycling ethanol, concentrate, vacuum drying gets dry extract, pulverize, standby.
Rhizoma Chuanxiong 1250g is ground into coarse powder, adds 2 times of amount 60% ethanol room temperatures dippings 2 times, each 12 hours, merges impregnation liquid.Decompression recycling ethanol concentrates, and layering gets Rhizoma Chuanxiong extract, and is standby.
(1). qi-circulation promoting soft capsule
Dry extract and Rhizoma Chuanxiong extract are merged, add Petiolus Trachycarpi oil 12%, Cera Flava 7%g, soybean oil is supplied final quantity, makes suspension.Be pressed into soft capsule rolling automatically on the mould machine.Through washing ball, drying, polishing, packing are promptly.
(2). pulse invigorating pill
Dry extract and Rhizoma Chuanxiong extract are merged, add 30% Polyethylene Glycol-4000,50%g Polyethylene Glycol-6000, stir and make whole dissolvings and mix homogeneously, keep splashing in the methyl-silicone oil (5～10 ℃) under 60 ℃ of constant temperatures, be condensed into drop pill.Blot methyl-silicone oil, the choosing grain, promptly.
Embodiment 3
Preparation technology
Radix Salviae Miltiorrhizae 1250g, Radix Puerariae 1250g are ground into coarse powder, add 5 times of amount 60% ethanol room temperatures dippings 4 times, each 20 hours, merge impregnation liquid.Decompression recycling ethanol also concentrates, and filters, and filtrate is crossed macroporous adsorbent resin AB-8 post, aqueous hydrochloric acid solution washing resin bed with the pH3 of 5 times of amounts of column volume, after washing post,, collect eluent with 50% ethanol elution of 5 times of amounts of column volume, decompression recycling ethanol, concentrate, vacuum drying gets dry extract, pulverize, standby.
Rhizoma Chuanxiong 1250g is ground into coarse powder, adds 4 times of amount 70% ethanol room temperatures dippings 2 times, each 20 hours, merges impregnation liquid.Decompression recycling ethanol concentrates, and layering gets Rhizoma Chuanxiong extract, and is standby.
(1). qi-circulation promoting soft capsule is made suspension.Be pressed into soft capsule rolling automatically on the mould machine.Through washing ball, drying, polishing, packing are promptly.
(2). pulse invigorating pill
Just dry extract and Rhizoma Chuanxiong extract merge, and add 70% Polyethylene Glycol-6000, stir and make whole dissolvings and mix homogeneously, keep splashing in the methyl-silicone oil (5～10 ℃) under 60 ℃ of constant temperatures, are condensed into drop pill, exhaust methyl-silicone oil, the choosing grain, promptly.
Embodiment 4
Preparation technology
Radix Salviae Miltiorrhizae 1250g, Radix Puerariae 1250g are ground into coarse powder, add 5 times of amount 60% ethanol room temperatures dippings 4 times, each 20 hours, merge impregnation liquid.Decompression recycling ethanol also concentrates, and filters, and filtrate is crossed macroporous adsorbent resin D101 post, aqueous hydrochloric acid solution washing resin bed with the pH2 of 3 times of amounts of column volume, after washing post,, collect eluent with 30% ethanol elution of 2 times of amounts of column volume, decompression recycling ethanol, concentrate, vacuum drying gets dry extract, pulverize, standby.
Rhizoma Chuanxiong 1250g is ground into coarse powder, adds 4 times of amount 75% ethanol room temperatures dippings 2 times, each 18 hours, merges impregnation liquid.Decompression recycling ethanol concentrates, and layering gets Rhizoma Chuanxiong extract, and is standby.
(1). qi-circulation promoting soft capsule
Above-mentioned two kinds of extracts merge, and add adjuvant Petiolus Trachycarpi oil 8%, Cera Flava 3%, and soybean oil is supplied final quantity, makes suspension.Be pressed into soft capsule rolling automatically on the mould machine.Through washing ball, drying, polishing, packing are promptly.
(2). pulse invigorating pill
Dry extract and Rhizoma Chuanxiong extract are merged, add 20%g Macrogol 4000,50% polyethylene glycol 6000, stir and make whole dissolvings and mix homogeneously, keep splashing in the white oil (5～10 ℃) under 60 ℃ of constant temperatures, be condensed into drop pill, exhaust white oil, the choosing grain, promptly.
Claims (7)
1, a kind of Chinese medicine preparation that is used for the treatment of ischemic cardio cerebrovascular diseases is characterized in that:
(1) Radix Salviae Miltiorrhizae, powder of Radix Puerariae are broken into coarse powder, add 2～10 times of 40～80% ethanol of medical material weight, room temperature dipping 2～5 times each 12～48 hours, merges impregnation liquid;
(2) concentrating under reduced pressure filters, and filtrate is crossed macroporous adsorptive resins, with the aqueous hydrochloric acid solution washing resin bed of pH2～7 of 3～10 times of amounts of column volume, after washing post,, collect eluent, concentrating under reduced pressure with 30～90% ethanol elutions of 2～5 times of amounts of column volume, vacuum drying gets dry extract, pulverizes standby;
(3) Rhizoma Chuanxiong power is broken into coarse powder, adds 2～10 times of amount 60～90% ethanol, room temperature dipping 2～5 times, each 12～48 hours, merge impregnation liquid, concentrating under reduced pressure, static layering, Rhizoma Chuanxiong extract, standby;
(4) in proportion above-mentioned 2,3 extracts are merged, add pharmaceutic adjuvant and make suspension, be pressed into soft capsule rolling automatically on the mould machine, through washing ball, drying, polishing, packing are promptly;
(5) in proportion above-mentioned 2,3 extracts are merged, add Polyethylene Glycol, stir and make whole dissolvings and mix homogeneously, keep under 60～90 ℃ of constant temperatures, splash in liquid paraffin or the methyl-silicone oil in 5～10 ℃, be condensed into drop pill, exhaust liquid paraffin or methyl-silicone oil, coating, the choosing grain, promptly.
2, Chinese medicine preparation as claimed in claim 1, wherein, described macroporous adsorptive resins is AB-8, D101.
3, Chinese medicine preparation as claimed in claim 1, wherein, the weight ratio of extract and pharmaceutic adjuvant is 1: 1～5 in the described soft capsule.
4, Chinese medicine preparation as claimed in claim 1, wherein, the weight ratio of extract and Polyethylene Glycol is 1: 2～8 in the described drop pill.
5, as claim 1 or 3 described Chinese medicine preparation, wherein, described pharmaceutic adjuvant is Petiolus Trachycarpi oil, Cera Flava, soybean oil.
6, as claim 1 or 4 described Chinese medicine preparation, wherein, described Polyethylene Glycol is Polyethylene Glycol 100,1000,4000 or 6000 and more than one mixture.
7, Chinese medicine preparation as claimed in claim 6, wherein, the weight ratio of described Macrogol 4000 and polyethylene glycol 6000 is 1: 1～4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100149708A CN1923227B (en) | 2005-09-02 | 2005-09-02 | Traditional Chinese medicinal formulation for treating ischemic cardiovascular and cerebrovascular diseases and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100149708A CN1923227B (en) | 2005-09-02 | 2005-09-02 | Traditional Chinese medicinal formulation for treating ischemic cardiovascular and cerebrovascular diseases and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1923227A true CN1923227A (en) | 2007-03-07 |
| CN1923227B CN1923227B (en) | 2010-08-11 |
Family
ID=37816169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005100149708A Expired - Fee Related CN1923227B (en) | 2005-09-02 | 2005-09-02 | Traditional Chinese medicinal formulation for treating ischemic cardiovascular and cerebrovascular diseases and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1923227B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103239506A (en) * | 2013-05-31 | 2013-08-14 | 成都百草和济科技有限公司 | Tongmai oral liquid raw material extract |
| CN103251677A (en) * | 2013-05-31 | 2013-08-21 | 成都百草和济科技有限公司 | Tongmai oral liquid raw material medicine extract and preparation method and application thereof |
| CN101612362B (en) * | 2009-07-29 | 2014-03-12 | 湖南福湘生物技术有限公司 | Complex preparation for regulating lipid and preventing and curing heart cerebrovascular diseases and preparation method thereof |
| CN104352530A (en) * | 2014-12-09 | 2015-02-18 | 山西黄河中医药研究所（有限公司） | Wax oil mixture obtained by extracting fat-soluble ingredients from traditional Chinese medicines |
| CN105168328A (en) * | 2015-09-07 | 2015-12-23 | 宜诺(天津)医药工程有限公司 | Kudzuvine root extract, extracting method and dropping pill of kudzuvine root extract |
| CN106361811A (en) * | 2016-09-21 | 2017-02-01 | 神威药业集团有限公司 | Tongmai pharmaceutical composition and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1088998C (en) * | 1999-01-30 | 2002-08-14 | 赫炎光 | Intravenous injection medicine for curing ischemic cerebrovascular disease and its preparing method |
| CN1650901A (en) * | 2004-02-02 | 2005-08-10 | 姜伟 | Method of extracting raw medicament for improving acute cardiomyopathy insufficient blood supply antianoxia from pure Chinese medical preparation |
-
2005
- 2005-09-02 CN CN2005100149708A patent/CN1923227B/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101612362B (en) * | 2009-07-29 | 2014-03-12 | 湖南福湘生物技术有限公司 | Complex preparation for regulating lipid and preventing and curing heart cerebrovascular diseases and preparation method thereof |
| CN103239506A (en) * | 2013-05-31 | 2013-08-14 | 成都百草和济科技有限公司 | Tongmai oral liquid raw material extract |
| CN103251677A (en) * | 2013-05-31 | 2013-08-21 | 成都百草和济科技有限公司 | Tongmai oral liquid raw material medicine extract and preparation method and application thereof |
| CN103239506B (en) * | 2013-05-31 | 2015-04-15 | 成都百草和济科技有限公司 | Tongmai oral liquid raw material extract |
| CN104352530A (en) * | 2014-12-09 | 2015-02-18 | 山西黄河中医药研究所（有限公司） | Wax oil mixture obtained by extracting fat-soluble ingredients from traditional Chinese medicines |
| CN104352530B (en) * | 2014-12-09 | 2017-05-10 | 山西黄河中医药研究所（有限公司） | Wax oil mixture obtained by extracting fat-soluble ingredients from traditional Chinese medicines |
| CN105168328A (en) * | 2015-09-07 | 2015-12-23 | 宜诺(天津)医药工程有限公司 | Kudzuvine root extract, extracting method and dropping pill of kudzuvine root extract |
| CN106361811A (en) * | 2016-09-21 | 2017-02-01 | 神威药业集团有限公司 | Tongmai pharmaceutical composition and preparation method thereof |
| CN106361811B (en) * | 2016-09-21 | 2019-11-22 | 神威药业集团有限公司 | One kind is promoted blood circulation pharmaceutical composition and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1923227B (en) | 2010-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101612362B (en) | Complex preparation for regulating lipid and preventing and curing heart cerebrovascular diseases and preparation method thereof | |
| CN101637484B (en) | Active extract for sanwei sandalwood as well as extraction method and medical application thereof | |
| CN1923227B (en) | Traditional Chinese medicinal formulation for treating ischemic cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1943618A (en) | Red sage root effective part standard extract and its preparing method and use | |
| CN102283895A (en) | Preparation technology and production method of integrated novel Lingguizhugan decoction dosage form | |
| CN1304769A (en) | Blood-cleaning pill | |
| CN103655673A (en) | Compound gingko dropping pill and preparation method thereof | |
| CN1660420A (en) | Compound combination of Chinese traditional medicine in use for lowering viscosity of whole blood, thrombolysis and reducing blood fat | |
| CN101757085A (en) | Chinese medicine preparation for treating ischemic cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1810268A (en) | Apoplexy treating medicine composition | |
| CN1272026C (en) | Medicinal composition for treating cardiocerebral vasculr disease and its preparing method | |
| CN1296087C (en) | Compound capsule for treating apoplexy involving the meridians of wind phlegm stasis blockage syndrome type and preparation process thereof | |
| CN1872099A (en) | Medication for treating cardiovascular diseases, and cerebrovascular disease | |
| CN1709225A (en) | Method for preparing health-care foods for auxiliary inhibiting tumour using polygonum cuspidatum extract | |
| CN1689637A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1626121A (en) | Preparation of Chinese traditional medicine for treating coronary heart disease and angina | |
| CN102058675A (en) | Traditional Chinese medicinal preparation for treating ischemic cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1872315A (en) | Application of medication of containing spatholobus stem in resistant medication anti aspirin | |
| CN1316992C (en) | Medicine for treating heart brain embulus disease and its preparation method | |
| CN1176648C (en) | Soft capsule in total flavone of hawthorn leaves and its preparing method | |
| CN1872317A (en) | Application of medication of containing red sage root in resistant medication anti aspirin | |
| CN1679831A (en) | Oral medicine for cardio-cerebral blood vessel diseases and its making method | |
| CN1714859A (en) | Use of composition containing red-rooted salvia root in preparing medicine for treating anti-aspirin | |
| CN1876033A (en) | Compound Chinese preparation with gingko, its preparation method and use | |
| CN1593574A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: TIANJIN TAIPU PHARMACEUTICAL INTELLECTUAL PROPERTY Free format text: FORMER OWNER: TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH Effective date: 20130130 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20130130 Address after: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee after: Tianjin Taipu Pharmaceutical Intellectual Property Flow Reserve Center Co, Ltd. Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee before: Tianjin Institute of Pharmaceutical Research |
|
| ASS | Succession or assignment of patent right |
Owner name: TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH Free format text: FORMER OWNER: TIANJIN TAIPU PHARMACEUTICAL INTELLECTUAL PROPERTY TRANSFER RESERVE CENTER CO., LTD. Effective date: 20140505 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20140505 Address after: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee after: Tianjin Institute of Pharmaceutical Research Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee before: Tianjin Taipu Pharmaceutical Intellectual Property Flow Reserve Center Co, Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100811 Termination date: 20170902 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |